Background
- ONB, SNEC and SNUC are rare sinonasal epithelial and neuroepithelial tumors for which there is no established systemic treatment standard of care for patients with recurrent/metastatic disease. Their rarity is an obstacle towards developing preclinical models and dedicated clinical trials.
- For ONB, transcriptomic similarities have been reported with glioblastoma, low-grade glioma, pheochromocytoma, paraganglioma, and more recently with small cell lung cancer (SCLC) [1,2]. Such studies are not available for SNUC and SNEC.
- We compared the transcriptomes of ONB, SNUC, SNEC, neuroendocrine (NE) and central nervous system tumor samples from a real-world (RW) patient cohort to identify similarities and uncover pharmacological vulnerabilities.